文献速递乳腺癌放疗放疗物理与技术

双侧区域淋巴结照射应用容积旋转调强放疗:剂量学分析与可行性

Bilateral Regional Nodal Irradiation Using Volumetric Modulated Arc Therapy: Dosimetric Analysis and Feasibility.
PubMed 文献 · Pract Radiat Oncol · 2022-01-16

本研究分析了2017至2020年在本机构接受容积旋转调强放疗(VMAT)行双侧区域淋巴结照射(RNI)的12例乳腺癌患者,中位随访14.5个月。结果显示VMAT可获得良好的靶区覆盖,双肺V5中位数为96.1%,心脏平均剂量中位数为699 cGy;5例(41%)发生1级咳嗽/呼吸困难,1例发生3级呼吸困难,无患者因肺部症状需医疗干预。作者认为VMAT对于需要双侧综合辅助放疗联合RNI的乳腺癌患者是可行且可耐受的放疗方式。

要点

  • 12例乳腺癌患者接受VMAT双侧RNI,双肺V5中位数为96.1%,心脏平均剂量中位数为699 cGy。
  • 5例(41%)发生1级咳嗽/呼吸困难,1例发生3级呼吸困难,无患者需糖皮质激素或呼吸干预。
  • 仅1例出现局部区域复发伴同步远处进展并死于疾病,截至末次随访未观察到第二原发癌。

核心结论

  • VMAT对于需要双侧综合辅助放疗联合RNI的乳腺癌患者似乎是可行且可耐受的放疗方式,可获得良好的靶区覆盖。
  • 尽管双肺V5中位数接近100%,无患者因肺部症状需要医疗干预,进一步提示V5不能预测并发症。

研究设计与样本

  • 分析2017年至2020年在本机构接受VMAT行双侧RNI的所有患者,回顾病历以获取临床病理特征、放疗参数和治疗相关不良事件。
  • 队列共纳入12例接受VMAT双侧RNI的患者,中位随访时间为14.5个月。

主要发现

  • 双肺V5中位数为96.1%(范围84.5%-99.8%),每侧肺V20中位数为27.5%(范围14.9%-38.1%)。
  • 心脏平均剂量中位数为699 cGy(范围527-1117 cGy)。
  • 5例(41%)发生1级咳嗽/呼吸困难,其中3例(60%)为当前或既往吸烟者;1例发生3级呼吸困难。
  • 无患者接受糖皮质激素治疗或需要呼吸干预,无患者出现长期肺部主诉。
  • 1例原有心脏疾病的患者出现射血分数下降,该患者同时接受了蒽环类化疗和曲妥珠单抗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Dosimetric and technical challenges often limit radiation therapy (RT) target coverage for patients with breast cancer who require bilateral breast/chest wall and regional nodal irradiation (RNI). We evaluated the feasibility of using volumetric modulated arc therapy (VMAT) to administer bilateral comprehensive RNI including the internal mammary nodes. METHODS AND MATERIALS: We analyzed all patients treated at our institution with bilateral RNI using VMAT between 2017 and 2020. Medical records were reviewed to ascertain clinicopathologic features, radiotherapeutic parameters, and treatment-related adverse events. RESULTS: The cohort was comprised of 12 patients who underwent VMAT for bilateral RNI, with a median follow-up time of 14.5 months. Median volume of the lung receiving 5 Gy (V5) for the bilateral lungs was 96.1% (range, 84.5%-99.8%), and median volume of the lung receiving 20 Gy for each lung was 27.5% (range, 14.9%-38.1%). The cardiac mean dose was a median of 699 cGy (range, 527-1117 cGy). Five patients (41%) developed grade 1 cough/dyspnea, with one patient developing grade 3 dyspnea. Of note, 3 of these patients (60%) were current or former smokers. No patient received glucocorticoid therapy or required respiratory intervention, and none developed longer-term pulmonary complaints. A decline in ejection fraction occurred in one patient with a preexisting cardiac condition who also received anthracycline-based chemotherapy and trastuzumab. Only one patient experienced a locoregional recurrence with synchronous distant progression, and subsequently succumbed to the disease. No secondary cancers have been noted to date. CONCLUSIONS: VMAT appears to be a feasible and tolerable RT modality for patients with breast cancer who require bilateral comprehensive adjuvant RT with RNI to obtain excellent target coverage. No patients required medical intervention for pulmonary complaints despite a median bilateral V5 approaching 100%, providing further evidence that V5 is not predictive for complications.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bernstein MB, Walker K, Gillespie E, et al. Bilateral Regional Nodal Irradiation Using Volumetric Modulated Arc Therapy: Dosimetric Analysis and Feasibility. Pract Radiat Oncol. 2022. PMID: 35045364. doi:10.1016/j.prro.2021.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。